CentpHarm.com
About CentpHarm.com
The first ( SAINT-1 ) trial, using NXY-059 to treat acute ischemic stroke, worked. However, the second ( SAINT-2 ) trial failed. Our proposals concerning the failure of SAINT-II are published in the journal Stroke as"SAINT-1 Worked, But the Neuroprotectant is not NXY-059" Basically, we suggest that the positive results of SAINT-1 occurred because of its well-known pharmacologically-active hydrolysis products, NtBHA and MNP.
